We promote progress
Our foundation supports the transfer of innovation from medical research to industry, in particular through young entrepreneurship in Switzerland. The foundation aims to strengthen Basel and Switzerland as a scientific and business location, also for the benefit of future generations. We invest in companies in Switzerland or abroad that are active in the field of life sciences and related fields. We value strong founding teams and high-quality science.
Portfolio
The JFG Life Sciences Foundation holds participations in the following companies:
- Amyl Therapeutics, Belgium
- Asterivir AG, Morges
- BioVersys AG, Basel
- Cathay Biotech, China
- cellvie, Zurich
- INOFEA AG, Muttenz
- Inthera Bioscience, Wädenswil
- MEMO Therapeutics, Schlieren
- MiniNaviDent AG, Liestal
- NXI Therapeutics AG, Basel
- Onconetix Inc, USA
- Perseo pharma AG, Muttenz
- Salvina Therapeutics, Allschwil
- TargImmune Therapeutics, Basel
- TECregen AG, Basel
Leadership
Patrick Burgermeister is a professional life science investor with a dual background in
molecular biology (Biozentrum Basel) and business administration (HSG St. Gallen). He has led the foundation since its inception in 2019 and was previously one of the partners at venture capital group BioMedPartners. His career also includes positions in banking (as a senior analyst for pharma/biotech) and in the pharmaceutical industry (as a senior portfolio manager at Novartis).
Patrick has been a successful business developer for early stage biotech companies, entering into collaboration and licensing agreements with public and private companies. He has led business development for several early stage companies including Apeiron Biologics and BioVersys.
Board of Trustees
- Dr. Jürg F. Geigy (President and founder)
- Dr. Matthias Staehelin (Vischer AG, lawyers and notaries)
- Prof. Dr. Torsten Schwede (Vice rector of research, University Basel)
- Dr. Peter E. Burckhardt (Startup expert)
News
- 2023.06.28 Cellvie strengthens team with CSO and COO
- 2023.11.07 Amyl Therapeutics receives EUR 5 mio funding
- 2024.05.07 BioVersys expands GSK collaboration and extends Series C
- 2024.06.18 NXI Therapeutics Financing Round
- 2024.07.08 MEMO Therapeutics announces Paul Carter as chairperson
- 2024.10.16 BioVersys recruits last patient in phase II pneumonia trial
- 2024.11.01 MEMO Therapeutics recruits last patient in BKV phase II trial
Contact
Are you interested to learn more or have a business plan that you would like to share with us? Then please write to patrick.burgermeister(at)jfgstiftung.ch